2020
DOI: 10.1101/2020.05.11.077651
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Low doses of radiation increase the immunosuppressive profile of lung macrophages during viral infection and pneumonia

Abstract: Patients with severe COVID-19 have a marked inflammatory state characterized by a cytokine storm syndrome. Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in 14% of the reported cases. Several therapeutic approaches are under investigation but safety and potential efficacy remain to be determined. Chest irradiation at equivalent doses below 1 Gy has been used successfully in the past to treat pneumonia.However, after the onset of effective antimicrobial agents, the use of… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
17
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(18 citation statements)
references
References 32 publications
1
17
0
Order By: Relevance
“…Of these, only 1.0 Gy demonstrated signs of efficacy, although we recognise that the other doses underwent less comprehensive evaluation. This observation is largely consistent with the data generated by Meziani and colleagues in lipopolysaccharide (LPS) and H1N1 influenza models of lung injury, although responses to 0.5 Gy were also observed in some of the histological and cytological readouts reported in this study (11).…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…Of these, only 1.0 Gy demonstrated signs of efficacy, although we recognise that the other doses underwent less comprehensive evaluation. This observation is largely consistent with the data generated by Meziani and colleagues in lipopolysaccharide (LPS) and H1N1 influenza models of lung injury, although responses to 0.5 Gy were also observed in some of the histological and cytological readouts reported in this study (11).…”
Section: Discussionsupporting
confidence: 93%
“…Recent preclinical studies have generated preliminary data to indicate that LDLR (0.5-1 Gy) reduces pneumonitis in lipopolysaccharide (LPS) and influenza virus mouse models (11). These diverse but limited bodies of evidence have underpinned early phase clinical trials of LDLR for acutely unwell COVID-19 patients in several countries including the USA, India and Spain.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, our patients did not receive the prescribed dose of 1 Gy to the whole lungs. Rather, as described in the manuscript, the lungs received antiinflammatory doses in the range of 0.5 -1.0 Gy, which appears adequate based on recent preclinical research [2,3].…”
Section: Separating Evidence From Opinion -In Regards To [Xxx] Et Almentioning
confidence: 99%
“…The M1-to M2-phenotypic conversion may be important to clinical outcomes of inflammatory disease, as the M2-type macrophages secrete the anti-inflammatory cytokines, interleukin (IL)-10 and TGF-b1 and suppress the proinflammatory cytokine IL-6. 33,34 Patients with critical COVID-19 illness (i.e.-hyperinflammation) have been shown to have high levels of cytokines, particularly IL-6 22 as constituent to cytokine storm. Downregulating proinflammatory cytokines in COVID-19 hyperinflammation could prevent the onset of a critical stage of disease.…”
Section: Covid-19 and Immunomodulation Through Ld-rtmentioning
confidence: 99%